Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (formerly Nasdaq: KRON) has generated a stream of news centered on its work as a biopharmaceutical and clinical-stage company focused on small molecule therapeutics that address deregulated transcription in cancer and autoimmune diseases. Company announcements describe how its proprietary discovery engine decodes transcription factor regulatory networks to identify druggable cofactors and support oncology and autoimmune programs.
News coverage for KRON has included scientific and pipeline updates, such as preclinical data from p300 lysine acetyltransferase (KAT) inhibitor programs in multiple myeloma, HPV-driven tumors, and autoimmune indications. Releases have detailed how p300 KAT inhibition can modulate pro-inflammatory signaling pathways, influence viral oncogene expression in HPV-driven tumor models, and support candidate selection for conditions such as Sjögren’s disease.
Corporate and strategic developments have also been prominent in Kronos Bio’s news flow. The company has reported decisions to discontinue development of a CDK9 inhibitor in a specific ovarian cancer setting, implement cost reduction strategies and workforce reductions, and evaluate strategic alternatives that could include acquisitions, mergers, or asset sales. These updates provide context on how Kronos Bio has managed its pipeline and resources.
A key news theme for KRON is the company’s acquisition by Concentra Biosciences, LLC. In May 2025, Kronos Bio announced a definitive merger agreement under which a Concentra subsidiary would launch a tender offer for all outstanding shares of Kronos Bio common stock for a cash payment per share plus a non-tradeable contingent value right tied to potential proceeds from specified product candidates and cost savings. A subsequent Form 8-K filed on June 20, 2025, reports that the tender offer was completed and the merger closed, with Kronos Bio becoming a wholly owned subsidiary of Concentra and its shares delisted from Nasdaq.
Investors, researchers, and observers reviewing KRON-related news can use this history to understand Kronos Bio’s scientific focus on deregulated transcription, the evolution of its pipeline, and the sequence of strategic decisions that culminated in its acquisition and delisting. This news archive offers a detailed record of how the company communicated scientific findings, financial results, restructuring measures, and corporate transactions over time.
Kronos Bio, Inc. (Nasdaq: KRON) mourns the loss of board member and early investor John C. Martin, Ph.D., who passed away recently. Martin was recognized for his significant contributions to the life sciences and was instrumental in the development of major HIV treatments during his tenure at Gilead Sciences. His legacy includes philanthropic efforts through The John C. Martin Foundation, focusing on healthcare access in underserved populations. Kronos Bio is committed to continuing Martin's vision of transforming cancer therapies through innovative research.
Kronos Bio (Nasdaq: KRON) announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Dr. Yang brings over 40 years of experience in pharma development, including significant roles at Gilead Sciences, where she led the creation of innovative treatments. Her expertise is expected to aid Kronos in advancing its clinical pipeline. Additionally, Jakob Loven will not seek re-election at the 2021 Annual Meeting. This change comes during a critical growth phase for Kronos, focused on cancer therapies like entospletinib and KB-0742.
Kronos Bio reported significant developments and financial results for 2020. They achieved an End-of-Phase 2 meeting with the FDA for entospletinib, targeting NPM1-mutated acute myeloid leukemia, and initiated a Phase 1/2 trial for KB-0742, a CDK9 inhibitor. The company ended 2020 with $462.1 million in cash and equivalents. For Q4 2020, R&D expenses totaled $13.1 million, with a net loss of $33.2 million ($0.70 per share). The company aims for a Phase 3 trial launch mid-2021, anticipating MRD negative CR data by late 2023.
Kronos Bio, Inc. (Nasdaq: KRON) has announced the presentation of pre-clinical data for KB-0742, a selective CDK9 inhibitor aimed at treating MYC-amplified solid tumors, at the AACR Annual Meeting 2021 from April 10-15. The study indicates that MYC genomic amplification may affect tumor sensitivity to CDK9 inhibition. A Phase 1/2 clinical trial for KB-0742 began earlier this year, with initial safety and pharmacokinetic data expected in Q4 2021, and expansion cohort data anticipated in 2022.
Kronos Bio announced its Phase 3 trial to assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint for potential accelerated FDA approval of entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia (AML). The trial is set to begin in mid-2021, with data expected in late 2023. This trial is notable as it marks the first use of MRD as a primary endpoint in AML, aimed at addressing the high mortality rate of this aggressive cancer. MRD negativity is linked to prolonged remissions and improved survival rates.
Kronos Bio has initiated a Phase 1/2 clinical trial for KB-0742, a selective CDK9 inhibitor targeting MYC-amplified solid tumors. The trial, involving 100 patients, aims to assess safety and pharmacokinetics, with initial data expected in Q4 2021. MYC-amplified tumors comprise approximately 30% of solid tumors, presenting a significant treatment opportunity. KB-0742, developed from Kronos' microarray platform, leverages its oral bioavailability and selectivity for CDK9, aiming to advance cancer treatment.
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the Cowen 41st Annual Health Care Conference, set for March 1-4, 2021. The company's CEO, Norbert Bischofberger, Ph.D., will contribute to a panel on "Novel Oncology Targets" on March 1 at 1:20 p.m. ET. Additionally, investor meetings are scheduled for March 2 and 3. Kronos Bio focuses on developing therapies targeting dysregulated transcription factors, with lead drug entospletinib aimed at NPM1-mutated acute myeloid leukemia, and KB-0742 for MYC-amplified solid tumors.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Marianne De Backer, Ph.D., to its board of directors, bringing over 20 years of healthcare industry experience. Rebecka Belldegrun, M.D., has resigned to pursue other opportunities. Dr. De Backer's extensive background includes leadership at Bayer AG and Johnson & Johnson, where she managed over 200 strategic alliances. She will contribute to the board's compensation committee as Kronos Bio approaches clinical testing for two investigational therapies targeting cancer treatment.
Kronos Bio, Inc. (Nasdaq: KRON) has appointed Pasit Phiasivongsa, Ph.D., as senior vice president of pharmaceutical development. With over 20 years in the biopharmaceutical field, he is expected to enhance the company's manufacturing processes as they prepare for clinical tests of KB-0742 and entospletinib. Dr. Phiasivongsa has a rich background in overseeing CMC strategies and has held significant roles in various companies. His appointment comes at a crucial time as Kronos Bio embarks on important clinical trials targeting cancer therapies.
Kronos Bio, Inc. (Nasdaq: KRON) has received FDA clearance for its Investigational New Drug (IND) application for KB-0742, an inhibitor targeting cyclin dependent kinase 9 (CDK9), aimed at treating MYC-amplified solid tumors. A Phase 1/2 clinical trial is set to commence in Q1 2021, assessing safety and pharmacokinetics. Approximately 30% of solid tumors exhibit MYC amplification, which is a key driver of cancer. Initial data from the trial is expected later in 2021, highlighting the company's commitment to developing innovative cancer therapies.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
